In conclusion, we have observed a 5-fold increase in risk of clinical events in T-allele carriers of the MMP-9 -1562 C/T polymorphism in CAD patients with MetS, probably mediated through altered MMP-9 regulation. This evidence concerns the gene MMP9 and metabolic syndrome.